Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Immunol Res. 2017 Nov 9;6(1):59–68. doi: 10.1158/2326-6066.CIR-17-0026

Figure 5. CD80-Fc prevents CTLA4-mediated suppression by saturating CTLA4.

Figure 5.

PHA-activated human PBMC, PDL1+ C8161 cells, and CD80-Fc (2 μg/ml) were incubated with increasing amounts of soluble CTLA4-Fc. or control irrelevant protein TROY-Fc. T cell activation was assessed by measuring IFNγ in the supernatants. Statistical analyses were performed using Student’s t test. Data are from one of two independent experiments.